News | Radiopharmaceuticals and Tracers | September 11, 2015

Westinghouse Signs Memorandum of Understanding with NorthStar to Produce Medical Radioisotopes

Partnership will work together to address global production capacity shortage of molybdenum-99

September 11, 2015 — Westinghouse Electric Company and NorthStar Medical Radioisotopes announced a memorandum of understanding to explore producing medical radioisotopes from the core of commercial nuclear reactors, and methods of global distribution. The exploration involves generating the most widely used radioisotope in medical diagnostic imaging by treating an isotope of the chemical element molybdenum rather than enriched uranium.

The effort is to address a global production capacity shortage of the medical radioisotope molybdenum-99 (Mo-99), as well as a nuclear proliferation concern with current methods, which rely on enriched uranium as source material. Both societal needs will be answered by using the highly reliable, high-volume production capacity of commercial nuclear reactors to make Mo-99 by irradiating molybdenum-98, and would require little capital investment by nuclear plant operators.

“Nuclear plants operate at very high capacity factors, and there are plants around the world that have the capability to produce Mo-99,” said Cindy Pezze, vice president and chief technology officer, Westinghouse. “Not only does commercial nuclear power provide reliable electricity without greenhouse gases, it can additionally contribute to society by making important diagnostic isotopes available globally.”

Westinghouse has a patent pending for producing medical radioisotopes using the existing Westinghouse plant design Incore Instrumentation System. NorthStar has been developing a process for using enriched Mo-98 targets as the starting point for Mo-99 rather than enriched uranium.

For more information: www.westinghousenuclear.com

Related Content

This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topics at the conference. #ASNC #ASNC19 #ASNC2019

This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topic at the conference.

Feature | Nuclear Imaging | November 22, 2019 | Dave Fornell, Editor
There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September...
Videos | Nuclear Imaging | November 07, 2019
American Society of Nuclear Cardiology (ASNC) President Rob Beanlands, M.D., shares a couple trends he sees in cardiac...
Videos | Nuclear Imaging | November 06, 2019
Doctor Robert Hendel explains some of the new cardiac radiotracers in the pipeline that were discussed in sessions at...
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. The image shows how SPECT allows the reader to distinguish between blood pool activity and radiotracer uptake.

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

Feature | Nuclear Imaging | July 22, 2019 | Christopher A. Hanson M.D., and Jamieson M. Bourque M.D., MHS
Cardiac amyloidosis is a highly morbid and underdiagnosed infiltrative cardiomyopathy that is characterized by the de
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Videos | Nuclear Imaging | August 21, 2018
Rami Doukky, M.D., professor of medicine, preventive medicine and radiology, and chief of the Division of Cardiology
ASNC Announces Keynote Speakers for 2018 Annual Scientific Session
News | Nuclear Imaging | August 08, 2018
August 8, 2018 — The American Society of Nuclear Cardiology’s (ASNC) Annual Scientific Session, ASNC2018, will kick o
Overlay Init